Navigation Links
LA BioMed research finds simpler way to assess breast cancer risk
Date:11/13/2007

TORRANCE (Nov. 13, 2007) - A new, simpler model for predicting breast cancer risk in postmenopausal women appears to be as accurate as a more complicated method currently used to decide if women would benefit from medication to reduce their risk of getting cancer, according to research published today in the Journal of the National Cancer Institute.

A team of researchers led by Rowan T. Chlebowski, a lead investigator at the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed), sought a simpler method for measuring breast cancer risk so women and their doctors could easily determine when the women would be likely to benefit from tamoxifen treatment for reducing their chances of getting breast cancer.

"For the first time, a postmenopausal woman can use a simple model and determine by herself if she is at increased risk of getting breast cancer, said Dr. Chlebowski. She could then raise this issue with her health care provider because interventions to reduce her risk of breast cancer are now available."

Using data from the Womens Health Initiative, a 15-year research program involving 161,808 postmenopausal women and funded by the National Institutes of Health, the researchers found postmenopausal women were at an increased risk of developing breast cancer if they were: 55 years of age or older and had either had a breast biopsy at any time, regardless of findings, or had a first-degree relative (mother, sister or daughter) who had breast cancer diagnosed at any age.

"Increased risk" is defined as about a 2 percent risk of developing breast cancer over the next five years. The researchers sought a quicker and easier way to determine risk because those who are at increased risk may benefit from tamoxifen treatment to reduce their chances of getting breast cancer.

Prior to this study, most physicians relied on the Gail Model to determine risk. But it involves so many variables that a c
'/>"/>

Contact: Laura Mecoy
lmecoy@issuesmanagement.com
310-546-5860
Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed)
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Response Biomedical appoints S. Wayne Kay Chief Executive Officer
2. Biomedtex Inc. Announces A. Marc Rocca as President and CEO
3. Hopes, Predictions and Realities: Is Biomedical Research Delivering On Its Promises?
4. Dr. Andrew K. Palmer Joins BMEs (BioMedical Enterprises, Inc.) Board of Directors
5. BioMed Realty Trust to Report 2007 Third Quarter Results
6. BME (BioMedical Enterprises, Inc.) Announces U.S. Launch of the OSSArc(TM) Anatomic Residual Compression Implant
7. Response Biomedical Corporation Receives Conditional Listing Approval from the Toronto Stock Exchange
8. BioMed Realty Trust Reports Third Quarter 2007 Financial Results
9. Stanford researchers find culprit in aging muscles that heal poorly
10. Children of depressed moms do better when dad is involved, SLU researcher finds
11. UCLA researchers identify markers that may predict diabetes in still-healthy people
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2008)...21 U.S. News & Worl...surance (NCQA) ranked BlueChoice(R) HealthPlan of ...Health Plans(TM), published in U.S. News & Wor...ted annual ranking ranks the nation,s best health ...on and NCQA accreditation scores. NCQA and U.S. Ne...
(Date:11/21/2008)... Nov. 21 Today, prescrip...ention in treating 88 percent of patients sufferin... treated for a chronic condition account for 96 pe...cent of all medical costs. A proprietary new phar...lth Solutions, Inc. (NYSE: MHS ) significantly r...
(Date:11/21/2008)... drugs do not cause genetic damage that can lead t... News) -- Two popular medications for treating att...t cause genetic damage linked to an increased risk... study, done by researchers at Duke University Med... counters a previous one that reported biomarkers ...
(Date:11/21/2008)...and deadly diseaseits cause remains a mysteryswept...ing with citizens, soldiers and refugees of the wa...s filled with corpses, social order broke down. Ov...e and Athens lost a third of its population. It lo...ginning of the end of the Golden Age of Greece. ,...
Breaking Medicine News(10 mins):Health News:BlueChoice HealthPlan Ranks in Top Third of America's Best Health Plans 2Health News:New Data: Advanced Pharmacy Model Significantly Reduces Gaps in Care for Patients with Chronic and Complex Conditions; Improves Clinical and Financial Outcomes 2Health News:New Data: Advanced Pharmacy Model Significantly Reduces Gaps in Care for Patients with Chronic and Complex Conditions; Improves Clinical and Financial Outcomes 3Health News:New Data: Advanced Pharmacy Model Significantly Reduces Gaps in Care for Patients with Chronic and Complex Conditions; Improves Clinical and Financial Outcomes 4Health News:New Data: Advanced Pharmacy Model Significantly Reduces Gaps in Care for Patients with Chronic and Complex Conditions; Improves Clinical and Financial Outcomes 5Health News:New Data: Advanced Pharmacy Model Significantly Reduces Gaps in Care for Patients with Chronic and Complex Conditions; Improves Clinical and Financial Outcomes 6Health News:ADHD Medications Don't Pose Cancer Risk 2Health News:Study of ancient and modern plagues finds common features 2Health News:Study of ancient and modern plagues finds common features 3Health News:Study of ancient and modern plagues finds common features 4
...ing a panic disorder may benefit more from treatme...ication instead // of the care usually offered by ...bling and costly anxiety disorders. In the study, ...nic disorder were randomly assigned to receive tre...
...t forgotten the thalidomide tragedy thalidomide in...tment of morning sickness // to pregnant mothers a.... Now, doctors see a new future use for the infamo...maintain their weight. The effects of this drug we...
...dy in Journal of Dental Research, caries in primar...nt teeth.// A primary tooth can have caries for a...alth or history, socio-economic status, years of e...ce to primary teeth, and early loss of primary tee...
...e of Journal of American Medical Association, rese...growing// trend in delaying the vaccination schedu...of the vaccinated diseases affecting the children....of the vaccines that need to be completed during t...
Other Medicine News:
(Date:11/19/2008)...ent from Roche- , , MONTVALE, N.J., Nov. 19...Corp. (Nasdaq: MEMY ) today announced that it ha...al of R3487/MEM 3454, its lead alpha-7 nicotinic r...d with schizophrenia (CIAS). The Company has rand...ng a $5.0 million payment from its partner Roche. ...
(Date:11/18/2008)...Newswire/ -- Arlington Medical Resources (AMR), a,...harmaceutical and diagnostic,imaging industries, ...gen was,sold in the U.S. during the third quarter...nous immune globulin (IVIG) and was launched in th...d from the blood plasma of thousands,of donors an...
(Date:11/18/2008)...oll newly diagnosed, elderly AML patients , ,...r Pharmaceuticals today announced that the first p...inical study of CPX-351 (Cytarabine:Daunorubicin) ...d acute myeloid leukemia (AML). , , The fir... Weill Medical College of Cornell University and...
(Date:11/13/2008)...ch Finds Statins Cut Risk of Heart Attacks, Deaths... Cardiovascular Disease,is the leading cause of de... hundreds of millions of dollars and causing untol...this fatal disease - even among those who,weren,t ...t millions of people could cut their risk of a,hea...
Breaking Medicine Technology:Memory Pharmaceuticals Achieves Enrollment Goal for Phase 2 Study of MEM 3454 in Cognitive Impairment Associated With Schizophrenia 2Memory Pharmaceuticals Achieves Enrollment Goal for Phase 2 Study of MEM 3454 in Cognitive Impairment Associated With Schizophrenia 3Over $10 Million of CSL Behring's Privigen Was Sold in the U.S. During the Third Quarter of 2008 2Celator(R) Pharmaceuticals Announces Enrollment of First Patient in Phase 2 Study with CPX-351 2Celator(R) Pharmaceuticals Announces Enrollment of First Patient in Phase 2 Study with CPX-351 3Seniors Can Be Heartened by New Study on Statins 2Independence Blue Cross and The Childrens Hospital of Philadelphia Reach Seven Year Agreement 13453 1Independence Blue Cross and The Childrens Hospital of Philadelphia Reach Seven Year Agreement 13453 2Independence Blue Cross and The Childrens Hospital of Philadelphia Reach Seven Year Agreement 13453 3Autism Society of America Hosts Day on the Hill 13449 1Autism Society of America Hosts Day on the Hill 13449 2Rare Gene Mutation Plays Role in Longevity 13445 1Rare Gene Mutation Plays Role in Longevity 13445 2Rare Gene Mutation Plays Role in Longevity 13445 3Women are treated less frequently than men with statins aspirin and beta blockers 13441 1Women are treated less frequently than men with statins aspirin and beta blockers 13441 2
...INCETON, N.J., June 14, 2007 /PRNewswire-FirstCall...tical company,committed to discovering, developing...fections, announced today that scientific,data pre...uring the,16th International HIV Drug Resistance W...une 12-15, 2007. The poster presentations,are avai...
...RCELONA, Spain, June 15, 2007 /PRNewswire-FirstCal... results regarding the,efficacy and safety of OREN... ongoing investigational study in children with ju...inadequate response to,one or more disease-modifyi...exate (MTX) or tumor necrosis factor (TNF) antagon...
Other Medicine Technology:Pharmasset Presents Clevudine and Racivir Data at the International,HIV Drug Resistance Workshop 2Pharmasset Presents Clevudine and Racivir Data at the International,HIV Drug Resistance Workshop 3Pharmasset Presents Clevudine and Racivir Data at the International,HIV Drug Resistance Workshop 4Pharmasset Presents Clevudine and Racivir Data at the International,HIV Drug Resistance Workshop 5Investigational Study Demonstrated a Re-Establishment of Clinical,Improvement with Orencia (Abatacept) in Children with Juvenile,Idiopathic Arthritis upon Re-Introduction of Therapy 2Investigational Study Demonstrated a Re-Establishment of Clinical,Improvement with Orencia (Abatacept) in Children with Juvenile,Idiopathic Arthritis upon Re-Introduction of Therapy 3Investigational Study Demonstrated a Re-Establishment of Clinical,Improvement with Orencia (Abatacept) in Children with Juvenile,Idiopathic Arthritis upon Re-Introduction of Therapy 4Investigational Study Demonstrated a Re-Establishment of Clinical,Improvement with Orencia (Abatacept) in Children with Juvenile,Idiopathic Arthritis upon Re-Introduction of Therapy 5Investigational Study Demonstrated a Re-Establishment of Clinical,Improvement with Orencia (Abatacept) in Children with Juvenile,Idiopathic Arthritis upon Re-Introduction of Therapy 6
...es is a national reference laboratory and a worldw...evelopment. ARUP offers an extensive test menu of ...l and anatomic pathology. Owned by the University ...han half of the nation's university teaching hospi...
...es is a national reference laboratory and a worldw...evelopment. ARUP offers an extensive test menu of ...l and anatomic pathology. Owned by the University ...han half of the nation's university teaching hospi...
...es is a national reference laboratory and a worldw...evelopment. ARUP offers an extensive test menu of ...l and anatomic pathology. Owned by the University ...han half of the nation's university teaching hospi...
...es is a national reference laboratory and a worldw...evelopment. ARUP offers an extensive test menu of ...l and anatomic pathology. Owned by the University ...han half of the nation's university teaching hospi...
Medicine Products: